Blood Tests of Non-Coding RNA in People With Psychiatric Disorders
Compares non-coding RNA levels in blood of adults with psychiatric disorders and healthy volunteers.
Plain-language title generated from the registry record
Registry title: Non-Coding RNAs Gene Expression in Psychiatric Disorders
Key facts
- Where
- Catania, Enna, Messina, and Palermo, ItalySee the 5 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT07649993, who can take part
Where in Italy
- Psychiatry Unit, Via Santa Sofia 78Catania, ItalyNo longer taking part
- Psychiatry Unit, Contrada Ferrante SNCEnna, ItalyNo longer taking part
- Cellular and Molecular Biology Laboratory, Tower of Biological Laboratories, 5th Floor Via Consolare Valeria 1Messina, ItalyNo longer taking part
- Psychiatry Unit, Via Consolare Valeria 1Messina, ItalyNo longer taking part
- Psychiatry Unit, Via del Vespro 129Palermo, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Carmen Concerto
- Trial code
- NCT07649993
- Record updated
- 23 June 2026
- Original description
This study aims to investigate whether specific non-coding RNAs, molecules involved in the regulation of gene expression, are altered in individuals with psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, panic disorder, and obsessive-compulsive disorder. Researchers will compare the expression levels of these molecules in patients who are drug-naïve or have been free from psychiatric treatment for at least six months with those observed in healthy volunteers.Read full original descriptionShow less
Gene Expression Analysis of Non-coding RNAs in Psychiatric Disorders
This study aims to investigate whether specific non-coding RNAs, molecules involved in the regulation of gene expression, are altered in individuals with psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, panic disorder, and obsessive-compulsive disorder. Researchers will compare the expression levels of these molecules in patients who are drug-naïve or have been free from psychiatric treatment for at least six months with those observed in healthy volunteers.
The study will also evaluate whether the expression of these non-coding RNAs changes after approximately five months of standard psychiatric treatment. Blood samples collected during routine clinical care will be used to measure the expression levels of selected non-coding RNAs using reverse transcription quantitative polymerase chain reaction (RT-qPCR), a laboratory technique used to assess gene expression.
This is an observational study and does not assign specific treatments. All therapies will be prescribed according to standard clinical practice.
The main objective is to determine whether alterations in non-coding RNA expression may serve as biological markers of psychiatric disorders and whether these markers may help monitor treatment-related changes over time. The findings may contribute to a better understanding of the biological mechanisms underlying major psychiatric disorders and support the future development of more accurate diagnostic and therapeutic approaches.
Inclusion: Age between 18 and 55 years; Male sex or female sex in the mid-luteal phase of the menstrual cycle; Clinical presentation consistent with diagnostic criteria for:; Bipolar Disorder type I or II,; Panic Disorder,; Major Depressive Disorder,; Obsessive-Compulsive Disorder,; Schizophrenia; First diagnosis and drug-naive status, or absence of psychopharmacological treatment for at least 6 months prior to enrollment; Age between 18 and 55 years; Male sex or female sex in the mid-luteal phase of the menstrual cycle; No treatment with psychotropic medications; Absence of clinical elements supporting a diagnosis of Bipolar Disorder, Panic Disorder, Major Depressive Disorder, Obsessive-Compulsive Disorder, Schizophrenia; Absence of clinical or laboratory evidence of infectious or internal medicine diseases; Absence of autoimmune diseases; HAM-D score < 8; MRS score < 11; Y-BOCS score < 7; BPRS score = 18; No significant stressful life events during the previous 6 months.
Exclusion: Current immunosuppressive, antibiotic, or hormone replacement therapy; Active infectious diseases or infections resolved less than 3 weeks before enrollment; Current psychopharmacological treatment or discontinuation of psychopharmacological therapy less than 6 months before enrollment; Relevant medical comorbidities, including autoimmune or internal medicine disorders; Relevant psychiatric comorbidities.